Type 2 Diabetes MellitusNCT05684406
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients
An observational study of Type 2 Diabetes Mellitus, run by Sohag University at 1 site in Egypt.
Trial summary
Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide. the mitochondrial genome contains multiple copies per cell. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes Mellitus
- What is being tested?
- Genotyping
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- Jan 2023to Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients with type 2 diabetes mellitus aged from 15 years and above, in internal medicine department of Sohag University Hospital and healthy controls of matched age and sex
Who may be able to join
- This study will include patients who have type 2 diabetes mellitus.
Who cannot join
- • Patients who have any other chronic illness.
- Patients who have cancer.
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Sohag Univversity
Sohag, 82515
Hend Muhammed Naguib, assistant lecturer, 01005287752, hendmnaguib@gmail.com
Marwa Shabaan Hashem, lecturer, 01011047016
About this study
Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide.
the mitochondrial genome contains multiple copies per cell. Because of its close proximity with higher levels of reactive oxidative species, mitochondrial DNA is prone to oxidative stress; which may lead to mitochondrial dysfunction, characterized by lowered oxidative capacity and reduction in energy production. Mitochondrial dysfunction is associated with aging process and can affect cellular functions and thereby results in a variety of human diseases such as cancer, neurodegenerative diseases, cardiovascular diseases, diabetes and metabolic syndrome .
Telomere length reflects the cumulative damage from those exposure factors and can be used as a potential indicator of biological aging. Shorter telomere length has been linked to the development of a variety of age-related diseases, such as cancer, cardiovascular disease and diabetes
Read the detailed description
Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide .The number of adults with type 2 diabetes mellitus is increasing worldwide and if the trend continues the number will rise to 693 million by 2045. Multiple risk factors have been associated with an increased risk of developing type 2 diabetes, including obesity, adverse lifestyle and genetic factors .
Mitochondria generate most of the cell's need for chemical energy in the form of ATP, and mitochondrial dysfunction has been implicated in various aspects of the development and complications of type 2 diabetes including insulin resistance, obesity and beta cell dysfunction. Mitochondrial DNA is a circular and double-stranded DNA molecule comprising 37 genes, of which 13 genes are involved in the electron transport chains and generation of ATP to provide energy for cells, while the remaining genes encode proteins involved in the assembly of amino acids into functional proteins . Unlike the nuclear genome, which normally has only two copies per cell, the mitochondrial genome contains multiple copies per cell. Because of its close proximity with higher levels of reactive oxidative species (ROS), mitochondrial DNA (mtDNA) is prone to oxidative stress; which may lead to mitochondrial dysfunction, characterized by lowered oxidative capacity and reduction in energy production. Mitochondrial dysfunction is associated with aging process and can affect cellular functions and thereby results in a variety of human diseases such as cancer, neurodegenerative diseases, cardiovascular diseases, diabetes and metabolic syndrome.On the other hand, improvement in mitochondrial function, even after critical illness, has been shown to be associated with better survival. Mitochondrial copy number (mtDNA-CN) is a surrogate marker of mitochondrial function . Higher mtDNA-CN is a biomarker of better mitochondrial function and vice versa. A lower mtDNA-CN has been observed in skeletal muscle and adipose tissue of individuals with obesity or type 2 diabetes .similarly, a lower mtDNA-CN in beta cells has also been associated with decreased beta cell function .
In recent years, the association between diabetes mellitus and accelerated biological aging, evaluated by the emerging biomarker (telomere length), has gained much attention.
Telomeres are DNA-protein complexes that cap the chromosomal DNA ends, which preserve genomic integrity and stability. Telomeres shorten during somatic cell division because DNA polymerase is unable to fully replicate the 3' end of DNA. This process can be reversed by an enzyme (telomerase) that is only active in certain replicating tissues, such as male germ cells and activated lymphocytes, stem cells and cancer cells . In normal human cells, telomerase levels are insufficient to maintain telomere length during cell division. When telomeres reach a critically short length, cell growth becomes limited and undergoes cellular senescence or apoptosis. Oxidative stress and chronic inflammation accelerate telomere attribution, resulting in replicative senescence and organ degeneration.Telomere length reflects the cumulative damage from those exposure factors and can be used as a potential indicator of biological aging. Shorter telomere length has been linked to the development of a variety of age-related diseases, such as cancer, cardiovascular disease and diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Being tested
- Genotyping
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GenotypingGenetic
Genotyping by Real Time PCR
| Study group | Role | What they receive |
|---|---|---|
| Group I | patients with type 2 diabetes mellitus Receives: Genetic: Genotyping | |
| Group II | apparently healthy controls with no chronic illness of matched age and sex Receives: Genetic: Genotyping |
What is being measured
The primary outcome is the main question the study is designed to answer.
evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients
evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabeticients pat patients by Real Time PCR
Measured: within 3 days after collection of samples
Secondary outcomes (1)
evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients
evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients
Measured: within 3 days after collection of samples
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2023
- Study startJan 2023 (estimated)
- Primary completionNov 2023 (estimated)
- Study completionDec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hend Muhammed Naguib Omar, Sohag University
- Investigators
- Hend Muhammed Naguib, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05684406
- Sponsor's protocol ID
- Soh-Med-22-12-19
- Status last verified
- Jan 2023
- First submitted
- 23 Dec 2022
- Last updated
- 13 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients
- ClinicalTrials.gov ID
- NCT05684406
- Acronym / sponsor ID
- Soh-Med-22-12-19
- Conditions
- Type 2 Diabetes Mellitus
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Jan 2023 (estimated)
- Primary completion
- Nov 2023 (estimated)
- Study completion
- Dec 2023 (estimated)
- First posted
- 13 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide.
the mitochondrial genome contains multiple copies per cell. Because of its close proximity with higher levels of reactive oxidative species, mitochondrial DNA is prone to oxidative stress; which may lead to mitochondrial dysfunction, characterized by lowered oxidative capacity and reduction in energy production. Mitochondrial dysfunction is associated with aging process and can affect cellular functions and thereby results in a variety of human diseases such as cancer, neurodegenerative diseases, cardiovascular diseases, diabetes and metabolic syndrome .
Telomere length reflects the cumulative damage from those exposure factors and can be used as a potential indicator of biological aging. Shorter telomere length has been linked to the development of a variety of age-related diseases, such as cancer, cardiovascular disease and diabetes
Detailed description
Type 2 diabetes mellitus, which is characterised by a combination of insulin resistance and insufficient insulin secretion is a major contributor to the burden of morbidity and mortality worldwide .The number of adults with type 2 diabetes mellitus is increasing worldwide and if the trend continues the number will rise to 693 million by 2045. Multiple risk factors have been associated with an increased risk of developing type 2 diabetes, including obesity, adverse lifestyle and genetic factors .
Mitochondria generate most of the cell's need for chemical energy in the form of ATP, and mitochondrial dysfunction has been implicated in various aspects of the development and complications of type 2 diabetes including insulin resistance, obesity and beta cell dysfunction. Mitochondrial DNA is a circular and double-stranded DNA molecule comprising 37 genes, of which 13 genes are involved in the electron transport chains and generation of ATP to provide energy for cells, while the remaining genes encode proteins involved in the assembly of amino acids into functional proteins . Unlike the nuclear genome, which normally has only two copies per cell, the mitochondrial genome contains multiple copies per cell. Because of its close proximity with higher levels of reactive oxidative species (ROS), mitochondrial DNA (mtDNA) is prone to oxidative stress; which may lead to mitochondrial dysfunction, characterized by lowered oxidative capacity and reduction in energy production. Mitochondrial dysfunction is associated with aging process and can affect cellular functions and thereby results in a variety of human diseases such as cancer, neurodegenerative diseases, cardiovascular diseases, diabetes and metabolic syndrome.On the other hand, improvement in mitochondrial function, even after critical illness, has been shown to be associated with better survival. Mitochondrial copy number (mtDNA-CN) is a surrogate marker of mitochondrial function . Higher mtDNA-CN is a biomarker of better mitochondrial function and vice versa. A lower mtDNA-CN has been observed in skeletal muscle and adipose tissue of individuals with obesity or type 2 diabetes .similarly, a lower mtDNA-CN in beta cells has also been associated with decreased beta cell function .
In recent years, the association between diabetes mellitus and accelerated biological aging, evaluated by the emerging biomarker (telomere length), has gained much attention.
Telomeres are DNA-protein complexes that cap the chromosomal DNA ends, which preserve genomic integrity and stability. Telomeres shorten during somatic cell division because DNA polymerase is unable to fully replicate the 3' end of DNA. This process can be reversed by an enzyme (telomerase) that is only active in certain replicating tissues, such as male germ cells and activated lymphocytes, stem cells and cancer cells . In normal human cells, telomerase levels are insufficient to maintain telomere length during cell division. When telomeres reach a critically short length, cell growth becomes limited and undergoes cellular senescence or apoptosis. Oxidative stress and chronic inflammation accelerate telomere attribution, resulting in replicative senescence and organ degeneration.Telomere length reflects the cumulative damage from those exposure factors and can be used as a potential indicator of biological aging. Shorter telomere length has been linked to the development of a variety of age-related diseases, such as cancer, cardiovascular disease and diabetes
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I | – | Genetic: Genotypingpatients with type 2 diabetes mellitus |
| Group II | – | Genetic: Genotypingapparently healthy controls with no chronic illness of matched age and sex |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with type 2 diabetes mellitus aged from 15 years and above, in internal medicine department of Sohag University Hospital and healthy controls of matched age and sex
Key inclusion criteria (1 listed)
- This study will include patients who have type 2 diabetes mellitus.
Key exclusion criteria (2 listed)
- • Patients who have any other chronic illness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GenotypingGenotyping by Real Time PCR | Genetic | Group I, Group II |
Primary outcome
evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients
Time frame: within 3 days after collection of samples
evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabeticients pat patients by Real Time PCR
1 secondary outcome
evaluate the potential of leukocyte telomere length as biomarker in type 2 diabetic patients
Time frame: within 3 days after collection of samples
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Type 2 Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hend Muhammed Naguib principal investigator
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes Mellitus, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Hend Muhammed Naguib (01005287752, hendmnaguib@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
evaluate the potential of peripheral blood mtDNA-CN as biomarker in type 2 diabetic patients (time frame: within 3 days after collection of samples). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2023.